Influenza roadmap:
Vaccines
Roadmap for the development of candidate vaccines for influenza
Download Influenza-vaccine-development-roadmap4
Inactivated vaccines
Inactivated vaccines
Research Question
- Fast production of highly immunogenic inactivated vaccines for novel
strains
Research Gaps and Challenges
- Low immune response
- Low speed of production for novel strains
- Rapid production of vaccine due to the limitation of virus growth on
eggs - Inactivated vaccines do not allow for mass application and need to
match the circulating strain to confer reasonable protection
Solution Routes
- Development of a suitable tissue culture system for production
- Strategies to increase mucosal immune responses after inactivated
vaccines - Novel/improved adjuvants
- Ability to overcome Maternally Derived Antibodies (MDA) interference.
- Build on improvement in humans research
Dependencies
- Identification of best vaccination strategies (Mucosal vs systemic protection vaccine for the whole year or specific period of time or season?)
State Of the Art
- Mostly egg based inactivated vaccines. Egg manufacturing platform is
costly, and supply is limited - Currently the inactivated vaccine provides suboptimal immunity in birds with maternally derived antibodies (MDA), but birds are vaccinated in ovo and day old in the hatchery
Projects
What activities are planned or underway?
Development of Vaccines for HPAI in Cattle, Turkey, Pigs, and Small Ruminants and Food Safety Studies Related to HPAI Virus in Food Products
Planned Completion date 25/08/2029
Source Countries:
United States
Automated non-invasive Detection of Surface Contamination and Optimizing Surface Biofilm Removal Conditions in Large-Scale Food Processing Equipment
Planned Completion date 31/08/2028
Source Countries:
United States